• Publications
  • Influence
Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy.
These studies provide clinical evidence for a subpopulation of chemotherapy-resistant breast cancer-initiating cells and, in combination with conventional therapy, specific pathway inhibitors may provide a therapeutic strategy for eliminating these cells to decrease recurrence and improve long-term survival. Expand
Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu
This pattern of hormone-dependent, TAM-resistant growth exhibited by the MCF/HER2–18 tumors in nude mice supports the possibility that p185HER2 overexpression in human breast cancers may be linked to therapeutic resistance. Expand
Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
It is hypothesized that ER+/PR- breast tumors are more likely than ER-/PR+ breast tumors to have an aggressive phenotype, to express HER-1 and overexpress HER-2, and are less likely to benefit from tamoxifen adjuvant therapy. Expand
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis
The recurrence score is prognostic for tamoxifen-treated patients with positive nodes and predicts significant benefit of CAF in tumours with a high recurrence scores, as well as overall survival and breast-cancer-specific survival. Expand
Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States.
Overall, white women were significantly more likely to be older and to have smaller tumors, have less lymph node involvement, have tumors with positive ER and PgR status, and have a lower S-phase fraction compared with Hispanic or black women. Expand
Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer.
BACKGROUND The p53 (also known as TP53) tumor suppressor gene encodes for a nuclear phosphoprotein thought to regulate proliferation of normal cells. Most p53 mutations result in a nonfunctionalExpand
Binding of CtIP to the BRCT Repeats of BRCA1 Involved in the Transcription Regulation of p21 Is Disrupted Upon DNA Damage*
It is suggested that the binding of the BRCT repeats of BRCA1 to CtIP/CtBP is critical in mediating transcriptional regulation of p21 in response to DNA damage. Expand
Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases.
When accurately measured, PgR status is an independent predictive factor for benefit from adjuvant endocrine therapy and should be taken into account when discussing RR reductions expected from endocrine treatment with individual patients. Expand
Tamoxifen in the treatment of breast cancer.
  • C. Osborne
  • Medicine
  • The New England journal of medicine
  • 1998
Re-expression of estrogen receptor alpha in estrogen receptor alpha-negative MCF-7 cells restores both estrogen and insulin-like growth factor-mediated signaling and growth.
Data show that ERalpha is a critical requirement for IGF signaling, and to the knowledge this is the first report of functional ERalpha expression that confers estrogen-mediated growth of an ER-negative breast cancer cell line. Expand